PHAR Stock Analysis: Buy, Sell, or Hold?
PHAR - Pharming Group N.V. ADS, each representing 10 ordinary shares
$10.67
1.02 (10.57%)
▲
5d:
+10.8%
30d:
-0.93%
90d:
-15.42%
WAIT
LOW Confidence
Analysis Updated: Oct 22, 2026 12:00 AM ET
Earnings: Nov 05, 2026
12d
Get Alerted When PHAR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: PHAR shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: PHAR is currently trading at $10.67, which is considered extended relative to its 30-day fair value range of $9.54 to $10.64. The stock's valuation (Forward PE: 162.9) is in line with its historical norms (174.4). Remarkably, the market is currently pricing in an annual earnings decline of 2.3% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is approaching resistance at $10.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.6% recently.
Market Sentiment: PHAR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+221.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, PHAR is in a strong downtrend. The price is approaching resistance at $10.80. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 10.6% recently.
Market Sentiment: PHAR scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $34.35 (+221.9%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.54 -
$10.64
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+10.6%)
- BULLISH: Trading 221.9% below Wall St target ($34.35)
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$9.54 -
$10.64
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$9.11
Resistance Level
$10.80
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
162.90
Wall Street Target
$34.35
(+221.9%)
Revenue Growth (YoY)
-3.2%
Earnings Growth (YoY)
-62.9%
Profit Margin
2.5%
Valuation Discount vs History
-2.3% cheaper
PE vs Historical
162.9 vs 174.4
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-2.3%
(market-implied from PE analysis)
1-Year Target
$10.42
(-2%)
2-Year Target
$10.18
(-5%)
3-Year Target
$9.95
(-7%)
3-Yr Target (if PE normalizes)
(PE: 163→174)
$10.65
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 162.9, Growth: -89.3%)
$7.78
(+-27%)
Base:
(SPY PE: 19.9, Growth: -89.3%)
$0.95
(-91%)
Bear:
(PE: 16.9, Growth: -89.3%)
$0.81
(-92%)
📈
Valuation based on Current Earnings
Trailing PE: 74.23 | Current EPS (TTM): $0.13
Bull Case
$5.35
(-50%)
Analyst growth -49.6%, PE expands to 81.7
Base Case
$4.86
(-54%)
Market implied -49.6%, PE stable at 74.2
Bear Case
$6.56
(-39%)
Severe decline -20.0%, PE contracts to 63.1
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 162.9 to 174.4
Stabilization Target:
$11.42
(+7.1%)
PE Expansion Potential:
+7.1%
Share & Embed Analysis
Last updated: October 23, 2026 4:07 AM ET
Data refreshes hourly during market hours. Next update: 5:07 AM
Data refreshes hourly during market hours. Next update: 5:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
22 analysts |
$295 | 62 BUY |
|
REGN
Regeneron Pharmaceutical… |
BUY
28 analysts |
$864 | 44 HOLD |
|
PRAX
Praxis Precision Medicin… |
STRONG BUY
20 analysts |
$650 | 61 BUY |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
17 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
STRONG BUY
20 analysts |
$31 | 66 BUY |
